 | • レポートコード：MRC23Q36439 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の渓谷熱治療薬市場について調査・分析し、世界の渓谷熱治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（フルコナゾール、ボリコナゾール、ポサコナゾール、アムホテリシンB、その他）、用途別セグメント分析（病院、小売店、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Bayer、Teva Pharmaceuticals、Apotex、Sanofi-Aventis、Hexal、Mylan、Baxter、Lunan Pharmaceutical、Yi Kang Pharm、Kelun、ShiJiaZhuang No.4 Pharmaceutical、Qilu Pharmaceutical Group、Minsheng Pharmaceuticalなどが含まれています。 世界の渓谷熱治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、渓谷熱治療薬市場規模を推定する際に考慮しました。本レポートは、渓谷熱治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、渓谷熱治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・渓谷熱治療薬市場の概要 - 渓谷熱治療薬のタイプ別セグメント - 世界の渓谷熱治療薬市場規模：タイプ別分析（フルコナゾール、ボリコナゾール、ポサコナゾール、アムホテリシンB、その他） - 渓谷熱治療薬の用途別セグメント - 世界の渓谷熱治療薬市場規模：用途別分析（病院、小売店、その他） - 世界の渓谷熱治療薬市場規模予測（2018年-2029年） ・渓谷熱治療薬市場の成長トレンド - 渓谷熱治療薬の地域別市場規模（2018年-2029年） - 渓谷熱治療薬市場ダイナミクス - 渓谷熱治療薬の業界動向 - 渓谷熱治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：フルコナゾール、ボリコナゾール、ポサコナゾール、アムホテリシンB、その他 - 世界の渓谷熱治療薬のタイプ別市場規模（2018年-2023年） - 世界の渓谷熱治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、小売店、その他 - 世界の渓谷熱治療薬の用途別市場規模（2018年-2023年） - 世界の渓谷熱治療薬の用途別市場規模（2024年-2029年） ・渓谷熱治療薬の地域別市場規模 - 北米の渓谷熱治療薬市場規模（2018年-2029年） - アメリカの渓谷熱治療薬市場規模（2018年-2029年） - ヨーロッパの渓谷熱治療薬市場規模（2018年-2029年） - アジア太平洋の渓谷熱治療薬市場規模（2018年-2029年） - 中国の渓谷熱治療薬市場規模（2018年-2029年） - 日本の渓谷熱治療薬市場規模（2018年-2029年） - 韓国の渓谷熱治療薬市場規模（2018年-2029年） - インドの渓谷熱治療薬市場規模（2018年-2029年） - オーストラリアの渓谷熱治療薬市場規模（2018年-2029年） - 中南米の渓谷熱治療薬市場規模（2018年-2029年） - 中東・アフリカの渓谷熱治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、Bayer、Teva Pharmaceuticals、Apotex、Sanofi-Aventis、Hexal、Mylan、Baxter、Lunan Pharmaceutical、Yi Kang Pharm、Kelun、ShiJiaZhuang No.4 Pharmaceutical、Qilu Pharmaceutical Group、Minsheng Pharmaceutical ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Valley Fever Medication market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Valley Fever Medication is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Valley Fever Medication is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Valley Fever Medication in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Valley Fever Medication include Pfizer, Bayer, Teva Pharmaceuticals, Apotex, Sanofi-Aventis, Hexal, Mylan, Baxter and Lunan Pharmaceutical, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Valley Fever Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Valley Fever Medication.
The Valley Fever Medication market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Valley Fever Medication market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Valley Fever Medication companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Bayer
Teva Pharmaceuticals
Apotex
Sanofi-Aventis
Hexal
Mylan
Baxter
Lunan Pharmaceutical
Yi Kang Pharm
Kelun
ShiJiaZhuang No.4 Pharmaceutical
Qilu Pharmaceutical Group
Minsheng Pharmaceutical
Segment by Type
Fluconazole
Voriconazole
Posaconazole
Amphotericin B
Others
Segment by Application
Hospital
Retail
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Valley Fever Medication companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Valley Fever Medication Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Fluconazole
1.2.3 Voriconazole
1.2.4 Posaconazole
1.2.5 Amphotericin B
1.2.6 Others
1.3 Market by Application
1.3.1 Global Valley Fever Medication Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Valley Fever Medication Market Perspective (2018-2029)
2.2 Valley Fever Medication Growth Trends by Region
2.2.1 Global Valley Fever Medication Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Valley Fever Medication Historic Market Size by Region (2018-2023)
2.2.3 Valley Fever Medication Forecasted Market Size by Region (2024-2029)
2.3 Valley Fever Medication Market Dynamics
2.3.1 Valley Fever Medication Industry Trends
2.3.2 Valley Fever Medication Market Drivers
2.3.3 Valley Fever Medication Market Challenges
2.3.4 Valley Fever Medication Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Valley Fever Medication Players by Revenue
3.1.1 Global Top Valley Fever Medication Players by Revenue (2018-2023)
3.1.2 Global Valley Fever Medication Revenue Market Share by Players (2018-2023)
3.2 Global Valley Fever Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Valley Fever Medication Revenue
3.4 Global Valley Fever Medication Market Concentration Ratio
3.4.1 Global Valley Fever Medication Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Valley Fever Medication Revenue in 2022
3.5 Valley Fever Medication Key Players Head office and Area Served
3.6 Key Players Valley Fever Medication Product Solution and Service
3.7 Date of Enter into Valley Fever Medication Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Valley Fever Medication Breakdown Data by Type
4.1 Global Valley Fever Medication Historic Market Size by Type (2018-2023)
4.2 Global Valley Fever Medication Forecasted Market Size by Type (2024-2029)
5 Valley Fever Medication Breakdown Data by Application
5.1 Global Valley Fever Medication Historic Market Size by Application (2018-2023)
5.2 Global Valley Fever Medication Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Valley Fever Medication Market Size (2018-2029)
6.2 North America Valley Fever Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Valley Fever Medication Market Size by Country (2018-2023)
6.4 North America Valley Fever Medication Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Valley Fever Medication Market Size (2018-2029)
7.2 Europe Valley Fever Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Valley Fever Medication Market Size by Country (2018-2023)
7.4 Europe Valley Fever Medication Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Valley Fever Medication Market Size (2018-2029)
8.2 Asia-Pacific Valley Fever Medication Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Valley Fever Medication Market Size by Region (2018-2023)
8.4 Asia-Pacific Valley Fever Medication Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Valley Fever Medication Market Size (2018-2029)
9.2 Latin America Valley Fever Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Valley Fever Medication Market Size by Country (2018-2023)
9.4 Latin America Valley Fever Medication Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Valley Fever Medication Market Size (2018-2029)
10.2 Middle East & Africa Valley Fever Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Valley Fever Medication Market Size by Country (2018-2023)
10.4 Middle East & Africa Valley Fever Medication Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Valley Fever Medication Introduction
11.1.4 Pfizer Revenue in Valley Fever Medication Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Valley Fever Medication Introduction
11.2.4 Bayer Revenue in Valley Fever Medication Business (2018-2023)
11.2.5 Bayer Recent Development
11.3 Teva Pharmaceuticals
11.3.1 Teva Pharmaceuticals Company Detail
11.3.2 Teva Pharmaceuticals Business Overview
11.3.3 Teva Pharmaceuticals Valley Fever Medication Introduction
11.3.4 Teva Pharmaceuticals Revenue in Valley Fever Medication Business (2018-2023)
11.3.5 Teva Pharmaceuticals Recent Development
11.4 Apotex
11.4.1 Apotex Company Detail
11.4.2 Apotex Business Overview
11.4.3 Apotex Valley Fever Medication Introduction
11.4.4 Apotex Revenue in Valley Fever Medication Business (2018-2023)
11.4.5 Apotex Recent Development
11.5 Sanofi-Aventis
11.5.1 Sanofi-Aventis Company Detail
11.5.2 Sanofi-Aventis Business Overview
11.5.3 Sanofi-Aventis Valley Fever Medication Introduction
11.5.4 Sanofi-Aventis Revenue in Valley Fever Medication Business (2018-2023)
11.5.5 Sanofi-Aventis Recent Development
11.6 Hexal
11.6.1 Hexal Company Detail
11.6.2 Hexal Business Overview
11.6.3 Hexal Valley Fever Medication Introduction
11.6.4 Hexal Revenue in Valley Fever Medication Business (2018-2023)
11.6.5 Hexal Recent Development
11.7 Mylan
11.7.1 Mylan Company Detail
11.7.2 Mylan Business Overview
11.7.3 Mylan Valley Fever Medication Introduction
11.7.4 Mylan Revenue in Valley Fever Medication Business (2018-2023)
11.7.5 Mylan Recent Development
11.8 Baxter
11.8.1 Baxter Company Detail
11.8.2 Baxter Business Overview
11.8.3 Baxter Valley Fever Medication Introduction
11.8.4 Baxter Revenue in Valley Fever Medication Business (2018-2023)
11.8.5 Baxter Recent Development
11.9 Lunan Pharmaceutical
11.9.1 Lunan Pharmaceutical Company Detail
11.9.2 Lunan Pharmaceutical Business Overview
11.9.3 Lunan Pharmaceutical Valley Fever Medication Introduction
11.9.4 Lunan Pharmaceutical Revenue in Valley Fever Medication Business (2018-2023)
11.9.5 Lunan Pharmaceutical Recent Development
11.10 Yi Kang Pharm
11.10.1 Yi Kang Pharm Company Detail
11.10.2 Yi Kang Pharm Business Overview
11.10.3 Yi Kang Pharm Valley Fever Medication Introduction
11.10.4 Yi Kang Pharm Revenue in Valley Fever Medication Business (2018-2023)
11.10.5 Yi Kang Pharm Recent Development
11.11 Kelun
11.11.1 Kelun Company Detail
11.11.2 Kelun Business Overview
11.11.3 Kelun Valley Fever Medication Introduction
11.11.4 Kelun Revenue in Valley Fever Medication Business (2018-2023)
11.11.5 Kelun Recent Development
11.12 ShiJiaZhuang No.4 Pharmaceutical
11.12.1 ShiJiaZhuang No.4 Pharmaceutical Company Detail
11.12.2 ShiJiaZhuang No.4 Pharmaceutical Business Overview
11.12.3 ShiJiaZhuang No.4 Pharmaceutical Valley Fever Medication Introduction
11.12.4 ShiJiaZhuang No.4 Pharmaceutical Revenue in Valley Fever Medication Business (2018-2023)
11.12.5 ShiJiaZhuang No.4 Pharmaceutical Recent Development
11.13 Qilu Pharmaceutical Group
11.13.1 Qilu Pharmaceutical Group Company Detail
11.13.2 Qilu Pharmaceutical Group Business Overview
11.13.3 Qilu Pharmaceutical Group Valley Fever Medication Introduction
11.13.4 Qilu Pharmaceutical Group Revenue in Valley Fever Medication Business (2018-2023)
11.13.5 Qilu Pharmaceutical Group Recent Development
11.14 Minsheng Pharmaceutical
11.14.1 Minsheng Pharmaceutical Company Detail
11.14.2 Minsheng Pharmaceutical Business Overview
11.14.3 Minsheng Pharmaceutical Valley Fever Medication Introduction
11.14.4 Minsheng Pharmaceutical Revenue in Valley Fever Medication Business (2018-2023)
11.14.5 Minsheng Pharmaceutical Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details